Gastrointestinal stromal tumor natural history: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}{{AE}}{{PSD}} | |||
{{Gastrointestinal stromal tumor}} | {{Gastrointestinal stromal tumor}} | ||
==Overview== | |||
==References== | ==Prognosis== | ||
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters (seeTable 1):[2,23-26] | |||
Mitotic index (mitoses per 50 high-power fields). | |||
Tumor size. | |||
Tumor location.==References== | |||
{{reflist|2}} | {{reflist|2}} | ||
| Line 10: | Line 16: | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:56, 2 September 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor natural history On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor natural history |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor natural history |
Overview
Prognosis
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters (seeTable 1):[2,23-26]
Mitotic index (mitoses per 50 high-power fields). Tumor size. Tumor location.==References==